3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
2
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Sezary Syndrome
1
Recurrence
1
Reconstructive Surgical Procedure
1
Neutropenia
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Neoplasm, Residual
1
Mycosis Fungoides
1
Multiple Myeloma
1
Motor Activity
1
Lymphopenia
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Large Granular Lymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Dupuytren Contracture
1
Congenital Abnormalities
1
Carcinoma, Renal Cell
1
Interventions
blinatumomab
3
Blood Specimen Collection
2
Azacitidine
2
venetoclax
1
ivosidenib
1
gilteritinib
1
daratumumab
1
avapritinib
1
Transplantation
1
Radiosurgery
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Lenalidomide
1
Interferon alpha-2
1
Inotuzumab Ozogamicin
1
Idarubicin
1
High-Throughput Nucleotide Sequencing
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
Consolidation Chemotherapy
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Neoplasm, Residual
×
Transplantation
×
Clear all
NCT07443592
2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA
Not yet recruiting
330 enrolled